US5045553A
(en)
*
|
1987-06-24 |
1991-09-03 |
Fujisawa Pharmaceutical Company, Ltd. |
Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
|
US4941457A
(en)
*
|
1989-08-17 |
1990-07-17 |
Olympus Optical Co., Ltd. |
Endoscope using an optical guide twisted on the tip side to have the visual field direction and curvature axis coincide with each other
|
IT1243745B
(it)
*
|
1990-10-17 |
1994-06-21 |
Vectorpharma Int |
Composizioni terapeutiche transdermali contenenti farmaco e/o agente promotore dell'assorbimento cutaneo supportato su particelle microporose e microsfere polimeriche e loro preparazione.
|
US5326566A
(en)
*
|
1991-05-17 |
1994-07-05 |
Bristol-Myers Squibb Company |
Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
|
US5985316A
(en)
*
|
1995-04-28 |
1999-11-16 |
Alza Corporation |
Composition and method of enhancing electrotransport agent delivery
|
US5990179A
(en)
*
|
1995-04-28 |
1999-11-23 |
Alza Corporation |
Composition and method of enhancing electrotransport agent delivery
|
US6420354B1
(en)
|
1998-06-08 |
2002-07-16 |
Advanced Medicine, Inc. |
Sodium channel drugs and uses
|
US6897305B2
(en)
|
1998-06-08 |
2005-05-24 |
Theravance, Inc. |
Calcium channel drugs and uses
|
US7101909B2
(en)
*
|
1998-10-12 |
2006-09-05 |
Theravance, Inc. |
Calcium channel drugs and uses
|
US6479498B1
(en)
|
1999-06-04 |
2002-11-12 |
Theravance, Inc. |
Sodium channel drugs and uses
|
USRE47351E1
(en)
|
1999-06-22 |
2019-04-16 |
Gilead Sciences, Inc. |
2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
|
US6403567B1
(en)
*
|
1999-06-22 |
2002-06-11 |
Cv Therapeutics, Inc. |
N-pyrazole A2A adenosine receptor agonists
|
US6214807B1
(en)
*
|
1999-06-22 |
2001-04-10 |
Cv Therapeutics, Inc. |
C-pyrazole 2A A receptor agonists
|
US6528511B2
(en)
|
2000-02-18 |
2003-03-04 |
Cv Therapeutics, Inc. |
Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
|
US20020012946A1
(en)
*
|
2000-02-23 |
2002-01-31 |
Luiz Belardinelli |
Method of identifying partial agonists of the A2A receptor
|
US7449454B2
(en)
*
|
2000-08-30 |
2008-11-11 |
Pharmacyclics, Inc. |
Metallotexaphyrin derivatives
|
US6638924B2
(en)
|
2000-08-30 |
2003-10-28 |
Pharmacyclics, Inc. |
Metallotexaphyrin derivatives
|
CA2429411A1
(en)
*
|
2000-11-17 |
2002-05-23 |
Pharmacyclics, Inc. |
Texaphyrin coordination compounds and uses thereof
|
AU3950802A
(en)
|
2000-12-07 |
2002-06-18 |
Cv Therapeutics Inc |
Abca-1 elevating compounds
|
US7157440B2
(en)
*
|
2001-07-13 |
2007-01-02 |
Cv Therapeutics, Inc. |
Partial and full agonists of A1 adenosine receptors
|
US7713946B2
(en)
*
|
2002-07-11 |
2010-05-11 |
Cv Therapeutics, Inc. |
Partial and full agonists A1 adenosine receptors
|
PL370207A1
(en)
|
2001-11-09 |
2005-05-16 |
Cv Therapeutics, Inc. |
A2b adenosine receptor antagonists
|
CN101392012A
(zh)
*
|
2002-02-19 |
2009-03-25 |
Cv医药有限公司 |
A1腺苷受体的部分和全促效药
|
US20030220344A1
(en)
|
2002-04-04 |
2003-11-27 |
Luiz Belardinelli |
Method of treating arrhythmias
|
IL165304A0
(en)
*
|
2002-05-21 |
2006-01-15 |
Cv Therapeutics Inc |
Method of treating diabetes
|
US8822473B2
(en)
*
|
2002-05-21 |
2014-09-02 |
Gilead Sciences, Inc. |
Method of treating diabetes
|
US20050020915A1
(en)
*
|
2002-07-29 |
2005-01-27 |
Cv Therapeutics, Inc. |
Myocardial perfusion imaging methods and compositions
|
KR20050026546A
(ko)
*
|
2002-07-29 |
2005-03-15 |
씨브이 쎄러퓨틱스, 인코포레이티드 |
A2a 수용체 작용제를 이용한 심근 관류 조영
|
US8470801B2
(en)
|
2002-07-29 |
2013-06-25 |
Gilead Sciences, Inc. |
Myocardial perfusion imaging methods and compositions
|
WO2004069818A1
(en)
|
2003-01-17 |
2004-08-19 |
Cv Therapeutics Inc. |
Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
|
US7732467B2
(en)
*
|
2003-05-15 |
2010-06-08 |
Alzheimer's Institute Of America, Inc. |
Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
|
AU2004287875B2
(en)
*
|
2003-11-05 |
2011-06-02 |
Bausch + Lomb Ireland Limited |
Modulators of cellular adhesion
|
JP5254616B2
(ja)
|
2004-09-13 |
2013-08-07 |
クロノ セラピューティクス、インコーポレイテッド |
生物学的同調性(biosynchronous)経皮的薬物送達
|
KR20070063548A
(ko)
|
2004-10-15 |
2007-06-19 |
씨브이 쎄러퓨틱스, 인코포레이티드 |
A2b 아데노신 수용체 길항제를 사용하는, 기도 개형 및폐 염증의 예방 및 치료 방법
|
WO2006044856A2
(en)
*
|
2004-10-20 |
2006-04-27 |
Cv Therapeuitics, Inc. |
Use of a2a adenosine receptor agonists
|
US20070087977A1
(en)
*
|
2004-11-16 |
2007-04-19 |
Wendye Robbins |
Methods and compositions for treating pain
|
JP2008520584A
(ja)
*
|
2004-11-16 |
2008-06-19 |
リマリック バイオファーマ,インコーポレイティド |
疼痛を治療するための方法と組成物
|
JP2006224318A
(ja)
*
|
2005-02-15 |
2006-08-31 |
Brother Ind Ltd |
インクジェット記録装置
|
WO2006119292A2
(en)
*
|
2005-04-29 |
2006-11-09 |
Henkin, Robert |
Methods for detection of biological substances
|
US8506934B2
(en)
*
|
2005-04-29 |
2013-08-13 |
Robert I. Henkin |
Methods for detection of biological substances
|
CA2985444C
(en)
|
2005-05-17 |
2019-03-12 |
Sarcode Bioscience Inc. |
Compositions and methods for treatment of eye disorders
|
EP2301937A1
(en)
*
|
2005-06-16 |
2011-03-30 |
Cv Therapeutics, Inc. |
Prodrugs of A2b adenosine receptor antagonists
|
CA2613703A1
(en)
*
|
2005-06-28 |
2007-01-04 |
Cv Therapeutics, Inc. |
Abca1 elevating compounds
|
US20070072838A1
(en)
|
2005-09-26 |
2007-03-29 |
Pharmacyclics, Inc. |
High-purity texaphyrin metal complexes
|
US20070078119A1
(en)
*
|
2005-09-30 |
2007-04-05 |
Pharmacyclics, Inc. |
Storage system for texaphyrin pharmaceutical formulations
|
KR101494125B1
(ko)
|
2006-02-03 |
2015-02-16 |
길리애드 사이언시즈, 인코포레이티드 |
A2a-아데노신 수용체 효능제 및 이의 다형체의 제조 방법
|
EP1989210A2
(en)
*
|
2006-03-02 |
2008-11-12 |
Cv Therapeutics, Inc. |
A2a adenosine receptor antagonists
|
US20070219174A1
(en)
*
|
2006-03-15 |
2007-09-20 |
Pharmacyclics, Inc. |
Methods of treating cancer using hypofractionated radiation and texaphyrins
|
US7702468B2
(en)
|
2006-05-03 |
2010-04-20 |
Population Diagnostics, Inc. |
Evaluating genetic disorders
|
US10522240B2
(en)
|
2006-05-03 |
2019-12-31 |
Population Bio, Inc. |
Evaluating genetic disorders
|
WO2008063712A1
(en)
*
|
2006-06-22 |
2008-05-29 |
Cv Therapeutics, Inc. |
Use of a2a adenosine receptor agonists in the treatment of ischemia
|
EP2046769A2
(en)
|
2006-07-27 |
2009-04-15 |
Cv Therapeutics, Inc. |
Aldh-2 inhibitors in the treatment of addiction
|
US20090081120A1
(en)
*
|
2006-09-01 |
2009-03-26 |
Cv Therapeutics, Inc. |
Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
|
US20080213165A1
(en)
*
|
2006-09-01 |
2008-09-04 |
Cv Therapeutics, Inc. |
Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods
|
US20080170990A1
(en)
*
|
2006-09-29 |
2008-07-17 |
Cv Therapeutics, Inc. |
Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease
|
US7893066B2
(en)
*
|
2006-10-05 |
2011-02-22 |
Gilead Palo Alto, Inc. |
Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
|
MX2009003658A
(es)
*
|
2006-10-05 |
2009-04-22 |
Cv Therapeutics Inc |
Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa.
|
CA2673653A1
(en)
*
|
2007-01-03 |
2008-07-17 |
Cv Therapeutics, Inc. |
Myocardial perfusion imaging
|
US8293489B2
(en)
|
2007-01-31 |
2012-10-23 |
Henkin Robert I |
Methods for detection of biological substances
|
US7718677B2
(en)
|
2007-04-02 |
2010-05-18 |
Parkinson's Institute |
Methods and compositions for reduction of side effects of therapeutic treatments
|
CA2681560A1
(en)
*
|
2007-04-09 |
2008-10-16 |
Cv Therapeutics, Inc. |
Pteridinone derivatives for use as stearoyl coa desaturase inhibitors
|
US20090105283A1
(en)
*
|
2007-04-11 |
2009-04-23 |
Dmitry Koltun |
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
US20080255161A1
(en)
*
|
2007-04-11 |
2008-10-16 |
Dmitry Koltun |
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
GB2463833B
(en)
*
|
2007-06-26 |
2012-02-08 |
Parkinson S Inst |
Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders
|
US20090012103A1
(en)
*
|
2007-07-05 |
2009-01-08 |
Matthew Abelman |
Substituted heterocyclic compounds
|
US20100093810A1
(en)
*
|
2007-10-05 |
2010-04-15 |
Alzheimer's Institute Of America, Inc. |
Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
|
US8236346B2
(en)
*
|
2007-10-05 |
2012-08-07 |
Alzheimer's Institute of America, Inc |
Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
|
ES2830024T3
(es)
|
2007-10-19 |
2021-06-02 |
Novartis Ag |
Composiciones y métodos para el tratamiento del edema macular
|
NZ587051A
(en)
|
2008-01-04 |
2012-12-21 |
Intellikine Llc |
Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase)
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
JP2011511802A
(ja)
*
|
2008-02-07 |
2011-04-14 |
ギリアード・パロ・アルト・インコーポレイテッド |
Abca−1を上昇させる化合物およびかかる化合物の使用方法
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤および使用方法
|
EP2268637A1
(en)
*
|
2008-04-04 |
2011-01-05 |
Gilead Sciences, Inc. |
Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors
|
EP2265124A4
(en)
*
|
2008-04-15 |
2011-12-28 |
Sarcode Bioscience Inc |
AEROSOLISED LFA-1 ANTAGONISTS FOR THE USE IN THE LOCAL TREATMENT OF IMMUNE DISEASES
|
EP2276508A4
(en)
*
|
2008-04-15 |
2011-12-28 |
Sarcode Bioscience Inc |
RELEASE OF LFA-1 ANTAGONISTS AGAINST THE GAS-DARM SYSTEM
|
EP3632444A3
(en)
*
|
2008-04-15 |
2020-08-26 |
SARcode Bioscience Inc. |
Topical lfa-1 antagonists for use in localized treatment of immune related disorders
|
WO2009139817A2
(en)
|
2008-04-15 |
2009-11-19 |
Sarcode Corporation |
Crystalline pharmaceutical and methods of preparation and use thereof
|
NZ590258A
(en)
|
2008-07-08 |
2013-10-25 |
Intellikine Llc |
Kinase inhibitors and methods of use
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
US8580801B2
(en)
|
2008-07-23 |
2013-11-12 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
BRPI0918962A2
(pt)
*
|
2008-09-29 |
2015-12-01 |
Gilead Sciences Inc |
combinações de um agente de controle de taxa e um antagonista do receptor a-2-alfa para utilização em métodos tomografia computadorizada de multidetectores
|
AU2009302241B2
(en)
|
2008-10-08 |
2015-10-29 |
Xgene Pharmaceutical Inc. |
GABA conjugates and methods of use thereof
|
US10098857B2
(en)
|
2008-10-10 |
2018-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
|
US20100267752A1
(en)
*
|
2008-10-15 |
2010-10-21 |
Gilead Palo Alto, Inc. |
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
WO2010074807A1
(en)
|
2008-10-30 |
2010-07-01 |
Gilead Palo Alto, Inc. |
3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
|
US8389500B2
(en)
|
2008-10-30 |
2013-03-05 |
Gilead Sciences, Inc. |
Fused heterocyclic compounds as ion channel modulators
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
US20100120727A1
(en)
*
|
2008-11-12 |
2010-05-13 |
Kyphia Pharmaceuticals, Inc. |
Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
|
CA2760791C
(en)
|
2009-05-07 |
2017-06-20 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
JP2012526848A
(ja)
*
|
2009-05-14 |
2012-11-01 |
ギリアード サイエンシーズ, インコーポレイテッド |
Cns障害の治療のためのラノラジン
|
US20110038852A1
(en)
*
|
2009-06-10 |
2011-02-17 |
3-V Biosciences, Inc. |
Antivirals that target transporters, carriers, and ion channels
|
TWI491606B
(zh)
|
2009-07-13 |
2015-07-11 |
Gilead Sciences Inc |
調節細胞凋亡信號之激酶的抑制劑
|
AU2010276537B2
(en)
|
2009-07-27 |
2015-04-16 |
Gilead Sciences, Inc. |
Fused heterocyclic compounds as ion channel modulators
|
US20110039799A1
(en)
|
2009-08-14 |
2011-02-17 |
Gilead Palo Alto, Inc. |
A1 adenosine receptor agonist polymorphs
|
EP2467141B1
(en)
|
2009-08-17 |
2018-10-31 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
WO2011050175A1
(en)
|
2009-10-21 |
2011-04-28 |
Sarcode Corporation |
Crystalline pharmaceutical and methods of preparation and use thereof
|
WO2011056985A2
(en)
|
2009-11-04 |
2011-05-12 |
Gilead Sciences, Inc. |
Substituted heterocyclic compounds
|
AU2011226689B2
(en)
|
2010-03-11 |
2016-09-01 |
Kronos Bio, Inc. |
Imidazopyridines Syk inhibitors
|
JP5951600B2
(ja)
|
2010-05-21 |
2016-07-13 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
キナーゼ調節のための、化合物、組成物および方法
|
MX2012015112A
(es)
|
2010-06-30 |
2013-05-28 |
Gilead Sciences Inc |
Uso de antagonistas del receptor de adenosina a2b para el tratamiento de la hipertension pulmonar.
|
AU2011272782B2
(en)
|
2010-07-02 |
2014-11-27 |
Gilead Sciences, Inc. |
Apoptosis signal-regulating kinase inhibitors
|
WO2012003392A1
(en)
|
2010-07-02 |
2012-01-05 |
Gilead Sciences, Inc. |
Fused heterocyclic compounds as ion channel modulators
|
CN103392182B
(zh)
|
2010-08-02 |
2017-07-04 |
众有生物有限公司 |
用于发现遗传疾病中致病突变的系统和方法
|
CN103298474B
(zh)
|
2010-11-10 |
2016-06-29 |
无限药品股份有限公司 |
杂环化合物及其用途
|
MY175521A
(en)
|
2011-01-07 |
2020-07-01 |
Allergan Inc |
Melanin modification compositions and methods of use
|
CA2824197C
(en)
|
2011-01-10 |
2020-02-25 |
Michael Martin |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
EP2678016B1
(en)
|
2011-02-23 |
2016-08-10 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
PT2683244T
(pt)
|
2011-03-08 |
2017-05-08 |
3-V Biosciences Inc |
Moduladores heterocíclicos de síntese de lipídios
|
AR085942A1
(es)
|
2011-04-07 |
2013-11-06 |
Gilead Sciences Inc |
Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
|
TWI510480B
(zh)
|
2011-05-10 |
2015-12-01 |
Gilead Sciences Inc |
充當離子通道調節劑之稠合雜環化合物
|
TWI478908B
(zh)
|
2011-07-01 |
2015-04-01 |
Gilead Sciences Inc |
作為離子通道調節劑之稠合雜環化合物
|
NO3175985T3
(fi)
|
2011-07-01 |
2018-04-28 |
|
|
TWI567061B
(zh)
|
2011-07-01 |
2017-01-21 |
吉李德科學股份有限公司 |
用於治療成癮之化合物
|
JP6027610B2
(ja)
|
2011-07-19 |
2016-11-16 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
CN103946226A
(zh)
|
2011-07-19 |
2014-07-23 |
无限药品股份有限公司 |
杂环化合物及其应用
|
TW201311663A
(zh)
|
2011-08-29 |
2013-03-16 |
Infinity Pharmaceuticals Inc |
雜環化合物及其用途
|
TWI468403B
(zh)
|
2011-08-30 |
2015-01-11 |
Gilead Sciences Inc |
用於治療成癮之aldh-2抑制劑
|
AU2012312266A1
(en)
|
2011-09-21 |
2013-05-02 |
Gilead Sciences, Inc. |
Sodium channel blockers reduce glucagon secretion
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
EP2766483B1
(en)
|
2011-10-10 |
2022-03-23 |
The Hospital For Sick Children |
Methods and compositions for screening and treating developmental disorders
|
US11180807B2
(en)
|
2011-11-04 |
2021-11-23 |
Population Bio, Inc. |
Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease
|
EP2812452B1
(en)
|
2012-02-09 |
2020-05-27 |
Population Bio, Inc. |
Methods and compositions for screening and treating developmental disorders
|
EP2817004B1
(en)
|
2012-02-22 |
2018-04-11 |
The Regents of The University of Colorado, A Body Corporate |
Bouvardin derivatives and therapeutic uses thereof
|
US9452215B2
(en)
|
2012-02-22 |
2016-09-27 |
The Regents Of The University Of Colorado |
Bourvadin derivatives and therapeutic uses thereof
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US8969588B2
(en)
|
2012-06-05 |
2015-03-03 |
Gilead Pharmasset Llc |
Solid forms of an antiviral compound
|
US9321749B1
(en)
|
2012-07-25 |
2016-04-26 |
Globavir Biosciences, Inc. |
Heterocyclic compounds and uses thereof
|
BR112015001608B1
(pt)
|
2012-07-25 |
2022-08-23 |
Novartis Ag |
Métodos para purificação e síntese de um composto inibidor lfa-1, mistura reacional e composições compreendendo o dito composto e composto isolado inibidor lfa-1
|
US8841340B2
(en)
|
2012-08-17 |
2014-09-23 |
Gilead Sciences, Inc. |
Solid forms of an antiviral compound
|
EP2895621B1
(en)
|
2012-09-14 |
2020-10-21 |
Population Bio, Inc. |
Methods and compositions for diagnosing, prognosing, and treating neurological conditions
|
EP2900835A4
(en)
|
2012-09-27 |
2016-05-11 |
Population Diagnotics Inc |
METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DEVELOPMENTAL DISORDERS
|
US20140120060A1
(en)
|
2012-11-01 |
2014-05-01 |
Infinity Pharmaceuticals, Inc. |
Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
|
JP6584952B2
(ja)
|
2012-11-01 |
2019-10-02 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
Pi3キナーゼアイソフォームモジュレーターを用いる癌の治療
|
BR112015014585A2
(pt)
|
2012-12-21 |
2017-07-11 |
Gilead Calistoga Llc |
composto, composição farmacêutica, e, método de tratamento de um ser humano
|
UY35212A
(es)
|
2012-12-21 |
2014-06-30 |
Gilead Sciences Inc |
Inhibidores de la quinasa que regula la señal de la apoptosis
|
ES2685568T3
(es)
|
2012-12-21 |
2018-10-10 |
Gilead Calistoga Llc |
Inhibidores de la isoquinolinona o quinazolinona fosfatidilinositol 3-quinasa
|
JP6154025B2
(ja)
|
2012-12-24 |
2017-06-28 |
ニューロガストルクス,インコーポレイテッド |
Gi管障害を治療するための方法
|
EP2970194A1
(en)
|
2013-03-15 |
2016-01-20 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
TWI530499B
(zh)
|
2013-03-28 |
2016-04-21 |
吉李德科學股份有限公司 |
作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類
|
TWI527811B
(zh)
|
2013-05-09 |
2016-04-01 |
吉李德科學股份有限公司 |
作爲溴結構域抑制劑的苯並咪唑衍生物
|
DK3003309T3
(da)
|
2013-05-30 |
2020-12-14 |
Infinity Pharmaceuticals Inc |
Behandling af cancer med PI3-kinase-isoform modulatorer
|
AU2014277950B2
(en)
|
2013-06-14 |
2016-02-04 |
Gilead Calistoga Llc |
Phosphatidylinositol 3-kinase inhibitors
|
BR112016001954A2
(pt)
|
2013-07-31 |
2017-08-01 |
Gilead Sciences Inc |
composto, composição farmacêutica, e, método para tratar uma doença ou condição
|
KR20160081908A
(ko)
|
2013-10-03 |
2016-07-08 |
쿠라 온콜로지, 인크. |
Erk의 억제제 및 사용 방법
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CA2925944C
(en)
|
2013-10-04 |
2023-01-10 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JP6262363B2
(ja)
|
2013-11-26 |
2018-01-17 |
ギリアード サイエンシーズ, インコーポレイテッド |
ブロモドメイン阻害剤としてのキノリン誘導体
|
CN105764516A
(zh)
|
2013-12-04 |
2016-07-13 |
吉利德科学公司 |
治疗癌症的方法
|
CA2931431A1
(en)
|
2013-12-05 |
2015-06-11 |
Acerta Pharma B.V. |
Therapeutic combination of a pi3k inhibitor and a btk inhibitor
|
SG11201604457XA
(en)
|
2013-12-19 |
2016-07-28 |
Gilead Sciences Inc |
Fused heterocyclic compounds as ion channel modulators
|
JP6568541B2
(ja)
|
2013-12-23 |
2019-08-28 |
ギリアド ファーマセット エルエルシー |
大環状hcv ns3阻害トリペプチドの結晶形態
|
TWI735853B
(zh)
|
2013-12-23 |
2021-08-11 |
美商克洛諾斯生技有限公司 |
脾酪胺酸激酶抑制劑
|
WO2015110923A2
(en)
|
2014-01-21 |
2015-07-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
|
TW201613908A
(en)
|
2014-02-13 |
2016-04-16 |
Gilead Sciences Inc |
Solid forms of an ion channel modulator
|
EP3108245B1
(en)
|
2014-02-18 |
2020-07-22 |
Robert I. Henkin |
Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
|
SG10201808053XA
(en)
|
2014-03-19 |
2018-10-30 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
WO2015181633A2
(en)
|
2014-04-11 |
2015-12-03 |
Acerta Pharma B.V. |
Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
WO2015185998A2
(en)
|
2014-04-11 |
2015-12-10 |
Acerta Pharma B.V. |
Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
WO2015175845A1
(en)
|
2014-05-15 |
2015-11-19 |
Peloton Therapeutics, Inc. |
Benzimidazole derivatives and uses thereof
|
TW201613916A
(en)
|
2014-06-03 |
2016-04-16 |
Gilead Sciences Inc |
TANK-binding kinase inhibitor compounds
|
JP6346964B2
(ja)
|
2014-06-13 |
2018-06-20 |
ギリアード サイエンシーズ, インコーポレイテッド |
ホスファチジルイノシトール3−キナーゼ阻害剤
|
KR20170012560A
(ko)
|
2014-06-13 |
2017-02-02 |
길리애드 사이언시즈, 인코포레이티드 |
포스파티딜이노시톨 3-키나제 억제제
|
CN110526912B
(zh)
|
2014-06-19 |
2023-02-14 |
武田药品工业株式会社 |
用于激酶抑制的杂芳基化合物
|
WO2015200369A1
(en)
|
2014-06-24 |
2015-12-30 |
Neurogastrx, Inc. |
Prodrugs of metopimazine
|
KR20170029580A
(ko)
|
2014-07-14 |
2017-03-15 |
길리애드 사이언시즈, 인코포레이티드 |
암을 치료하기 위한 조합물
|
US10759836B2
(en)
|
2014-07-18 |
2020-09-01 |
University Of Washington |
Cancer vaccine compositions and methods of use thereof
|
TW201609099A
(zh)
|
2014-08-11 |
2016-03-16 |
艾森塔製藥公司 |
使用布魯頓(Bruton)氏酪胺酸激酶(BTK)抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
|
TW201618774A
(zh)
|
2014-08-11 |
2016-06-01 |
艾森塔製藥公司 |
使用btk抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法
|
GB2558326B
(en)
|
2014-09-05 |
2021-01-20 |
Population Bio Inc |
Methods and compositions for inhibiting and treating neurological conditions
|
AU2015320675B2
(en)
|
2014-09-26 |
2018-10-18 |
Gilead Sciences, Inc. |
Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2016055982A1
(en)
|
2014-10-10 |
2016-04-14 |
Acerta Pharma B.V. |
Quinoline and quinazoline compounds
|
EP3209647B1
(en)
|
2014-10-21 |
2020-06-03 |
ARIAD Pharmaceuticals, Inc. |
Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl]pyrimidine-2,4-diamine
|
WO2016087994A1
(en)
|
2014-12-05 |
2016-06-09 |
Acerta Pharma B.V. |
Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
|
MA41252A
(fr)
|
2014-12-23 |
2017-10-31 |
Gilead Sciences Inc |
Formes solides d'un inhibiteur d'ask 1
|
DK3251699T3
(da)
|
2015-01-28 |
2024-05-21 |
Univ Duke |
Sammensætning omfattende methylphenidat og ondansetron til anvendelse i stofrelaterede forstyrrelser
|
EP3250258A4
(en)
|
2015-01-28 |
2018-09-05 |
Chrono Therapeutics, Inc. |
Drug delivery methods and systems
|
EP3267792A4
(en)
|
2015-03-11 |
2018-09-26 |
Peloton Therapeutics, Inc. |
Compositions for use in treating pulmonary arterial hypertension
|
US10155726B2
(en)
|
2015-03-11 |
2018-12-18 |
Peloton Therapeutics, Inc. |
Substituted pyridines and uses thereof
|
ES2910049T3
(es)
|
2015-03-19 |
2022-05-11 |
Sagimet Biosciences Inc |
Moduladores heterocíclicos de la síntesis de lípidos
|
EP3456717B1
(en)
|
2015-07-06 |
2021-03-17 |
Gilead Sciences, Inc. |
4,6-diamino-quinoline-3-carbonitrile derivative as cancer osaka thyroid (cot) modulator for treating inflammatory disease
|
EP3319938B1
(en)
|
2015-07-10 |
2022-04-06 |
University of Maryland, Baltimore |
Small molecule inhibitors of the mcl-1 oncoprotein and uses thereof
|
US20190008859A1
(en)
|
2015-08-21 |
2019-01-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
|
US20190022092A1
(en)
|
2015-09-15 |
2019-01-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
WO2017083488A1
(en)
|
2015-11-11 |
2017-05-18 |
Warner Babcock Institute for Green Chemistry |
Benzofuran derivatives for the treatment of cns and other disorders
|
AU2016370916A1
(en)
|
2015-12-17 |
2018-06-07 |
Gilead Sciences, Inc. |
Tank-binding kinase inhibitor compounds
|
WO2017122175A1
(en)
|
2016-01-13 |
2017-07-20 |
Acerta Pharma B.V. |
Therapeutic combinations of an antifolate and a btk inhibitor
|
WO2017147328A1
(en)
|
2016-02-23 |
2017-08-31 |
Portola Pharmaceuticals, Inc. |
Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
JP2019510752A
(ja)
|
2016-03-04 |
2019-04-18 |
ギリアード サイエンシーズ, インコーポレイテッド |
オートタキシン阻害剤の組成物及び合剤
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2017218802A1
(en)
|
2016-06-15 |
2017-12-21 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2017223284A1
(en)
|
2016-06-23 |
2017-12-28 |
University Of Maryland, Baltimore |
NON-CATALYTIC SUBSTRATE-SELECTIVE P38α-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF
|
AU2017289158C1
(en)
|
2016-06-30 |
2020-07-23 |
Gilead Sciences, Inc. |
4,6-diaminoquinazolines as Cot modulators and methods of use thereof
|
CA3036384A1
(en)
|
2016-09-14 |
2018-03-22 |
Gilead Sciences, Inc. |
Syk inhibitors
|
TW201822764A
(zh)
|
2016-09-14 |
2018-07-01 |
美商基利科學股份有限公司 |
Syk抑制劑
|
WO2018055577A1
(en)
|
2016-09-23 |
2018-03-29 |
Synthena Ag |
Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
|
WO2018057808A1
(en)
|
2016-09-23 |
2018-03-29 |
Gilead Sciences, Inc. |
Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
WO2018075601A1
(en)
|
2016-10-18 |
2018-04-26 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2018085818A1
(en)
|
2016-11-07 |
2018-05-11 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2018085833A2
(en)
|
2016-11-07 |
2018-05-11 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
|
WO2018098499A1
(en)
|
2016-11-28 |
2018-05-31 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
US11261188B2
(en)
|
2016-11-28 |
2022-03-01 |
Praxis Precision Medicines, Inc. |
Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
|
AR110252A1
(es)
|
2016-11-30 |
2019-03-13 |
Gilead Sciences Inc |
Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
|
AU2018205529B2
(en)
|
2017-01-06 |
2023-08-10 |
Morningside Venture Investments Limited |
Transdermal drug delivery devices and methods
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
CA3049435A1
(en)
|
2017-01-09 |
2018-07-12 |
Scott Grindrod |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US10240205B2
(en)
|
2017-02-03 |
2019-03-26 |
Population Bio, Inc. |
Methods for assessing risk of developing a viral disease using a genetic test
|
JOP20180009A1
(ar)
|
2017-02-06 |
2019-01-30 |
Gilead Sciences Inc |
مركبات مثبط فيروس hiv
|
WO2018148745A1
(en)
|
2017-02-13 |
2018-08-16 |
Praxis Precision Medicines , Inc. |
Compounds and their methods of use
|
WO2018152548A1
(en)
|
2017-02-20 |
2018-08-23 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2018152501A1
(en)
|
2017-02-20 |
2018-08-23 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2018160855A1
(en)
|
2017-03-01 |
2018-09-07 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2018160824A1
(en)
|
2017-03-01 |
2018-09-07 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2018175324A1
(en)
|
2017-03-20 |
2018-09-27 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
US11731966B2
(en)
|
2017-04-04 |
2023-08-22 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
WO2018195471A1
(en)
|
2017-04-21 |
2018-10-25 |
Gilead Sciences, Inc. |
Syk inhibitors in combination with hypomethylating agents
|
US11286233B2
(en)
|
2017-05-09 |
2022-03-29 |
Ambient Photonics, Inc. |
Stilbene derivatives for the treatment of CNS and other disorders
|
US11622960B2
(en)
|
2017-06-19 |
2023-04-11 |
University Of Maryland, Baltimore |
Microtubule polymerization inhibitor prodrugs and methods of using the same
|
US10570140B2
(en)
|
2017-08-09 |
2020-02-25 |
Prelude Therapeutics Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
|
WO2019035951A1
(en)
|
2017-08-15 |
2019-02-21 |
Praxis Precision Medicines, Inc. |
COMPOUNDS AND THEIR METHODS OF USE
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
TWI687415B
(zh)
|
2017-08-17 |
2020-03-11 |
美商基利科學股份有限公司 |
Hiv蛋白質膜抑制劑之固體形式
|
WO2019040102A1
(en)
|
2017-08-22 |
2019-02-28 |
Gilead Sciences, Inc. |
THERAPEUTIC HETEROCYCLIC COMPOUNDS
|
US11331288B2
(en)
|
2017-09-14 |
2022-05-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Conditioning irradiated tissue for increasing vascularity
|
WO2019067974A1
(en)
|
2017-09-28 |
2019-04-04 |
Medical Pharmaceuticals, Inc. |
ANTI-INFLAMMATORY, ANTICANCER AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING AND USING THEM
|
JOP20180092A1
(ar)
|
2017-10-13 |
2019-04-13 |
Gilead Sciences Inc |
مثبطات hiv بروتياز
|
CA3079545A1
(en)
|
2017-10-26 |
2019-05-02 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
US20200340060A1
(en)
|
2017-11-13 |
2020-10-29 |
Gilead Sciences, Inc. |
Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes
|
CA3087565A1
(en)
|
2018-01-09 |
2019-07-18 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
EP3752495B1
(en)
|
2018-02-15 |
2023-07-19 |
Gilead Sciences, Inc. |
Pyridine derivatives and their use for treating hiv infection
|
CN112055712B
(zh)
|
2018-02-16 |
2023-07-14 |
吉利德科学公司 |
用于制备可用于治疗逆转录病毒科病毒感染的治疗性化合物的方法和中间体
|
JP7295128B2
(ja)
|
2018-03-02 |
2023-06-20 |
オレゴン ヘルス アンド サイエンス ユニバーシティ |
小分子核内受容体モジュレータのアミドプロドラッグ
|
CN111971288B
(zh)
|
2018-03-14 |
2023-12-01 |
普莱鲁德疗法有限公司 |
蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
|
US10711007B2
(en)
|
2018-03-14 |
2020-07-14 |
Prelude Therapeutics Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
|
WO2019196622A1
(zh)
|
2018-04-09 |
2019-10-17 |
威尚(上海)生物医药有限公司 |
具有穿过血脑屏障能力的5取代二氟哌啶化合物
|
AU2019271799B2
(en)
|
2018-05-14 |
2023-10-12 |
Xgene Pharmaceutical Inc. |
Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin
|
JP7420797B2
(ja)
|
2018-05-29 |
2024-01-23 |
モーニングサイド ベンチャー インベストメンツ リミテッド |
薬剤送達の方法及びシステム
|
CA3101324A1
(en)
|
2018-05-30 |
2019-12-05 |
Praxis Precision Medicines, Inc. |
Ion channel modulators
|
CA3103987C
(en)
|
2018-07-06 |
2023-08-01 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
WO2020010223A1
(en)
|
2018-07-06 |
2020-01-09 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
TWI814350B
(zh)
|
2018-07-16 |
2023-09-01 |
美商基利科學股份有限公司 |
用於治療hiv之蛋白殼抑制劑
|
TWI829205B
(zh)
|
2018-07-30 |
2024-01-11 |
美商基利科學股份有限公司 |
抗hiv化合物
|
FI3625368T3
(fi)
|
2018-08-08 |
2023-01-13 |
|
Menetelmiä john cunningham -viruksen aiheuttaman progressiivin multifokaalin leukoenkefalopatian kehittymisen riskin arviointiin geneettisellä testauksella
|
JP2021535159A
(ja)
|
2018-08-27 |
2021-12-16 |
スピノジェニックス, インコーポレイテッド |
スパイン形成のためのファシン結合化合物
|
ES2966707T3
(es)
|
2018-10-01 |
2024-04-23 |
Global Blood Therapeutics Inc |
Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
|
WO2020072656A1
(en)
|
2018-10-03 |
2020-04-09 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
FI3873903T3
(fi)
|
2018-10-31 |
2024-03-26 |
Gilead Sciences Inc |
Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
|
CN113166173A
(zh)
|
2018-11-09 |
2021-07-23 |
普莱鲁德疗法有限公司 |
作为骨髓细胞白血病1(mcl-1)蛋白抑制剂的螺-磺酰胺衍生物
|
RS62970B1
(sr)
|
2018-11-19 |
2022-03-31 |
Global Blood Therapeutics Inc |
2-formil-3-hidroksifeniloksimetil jedinjenja sposobna da moduliraju hemoglobin
|
EP3890733A4
(en)
|
2018-12-07 |
2022-05-04 |
University of Maryland, Baltimore |
INHIBITORS OF P38 MITOGEN-ACTIVATED PROTEIN KINASE AT NON-ATP/CATALYTIC SITE
|
JP2022513449A
(ja)
|
2018-12-12 |
2022-02-08 |
オートバーン セラピューティクス,インク. |
新規な甲状腺模倣物
|
EP3894416B1
(en)
|
2018-12-13 |
2022-11-09 |
Global Blood Therapeutics, Inc. |
Ferroportin inhibitors and methods of use
|
WO2020123994A1
(en)
|
2018-12-14 |
2020-06-18 |
Prelude Therapeutics, Incorporated |
2-((5-(phenyl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-3-(phenyl)propanoic acid derivatives and related compounds as mcl-1 enzyme inhibitors for treating cancer
|
WO2020163637A1
(en)
|
2019-02-06 |
2020-08-13 |
Oregon Health & Science University |
Bisphosphonate-linked compounds
|
EP3924360A1
(en)
|
2019-02-13 |
2021-12-22 |
Prelude Therapeutics, Incorporated |
Selective inhibitor of protein arginine methyltransferase 5 (prmt5)
|
AU2020225455A1
(en)
|
2019-02-22 |
2021-09-09 |
Kronos Bio, Inc. |
Solid forms of condensed pyrazines as Syk inhibitors
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
EP3931186A1
(en)
|
2019-02-25 |
2022-01-05 |
CHDI Foundation, Inc. |
Compounds for targeting mutant huntingtin protein and uses thereof
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
CN113784950A
(zh)
|
2019-03-01 |
2021-12-10 |
速通医疗公司 |
新型拟甲状腺素药
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
WO2020227101A1
(en)
|
2019-05-03 |
2020-11-12 |
Praxis Precision Medicines, Inc. |
Kcnt1 inhibitors and methods of use
|
US11773099B2
(en)
|
2019-05-28 |
2023-10-03 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
US11279700B2
(en)
|
2019-05-31 |
2022-03-22 |
Praxis Precision Medicines, Inc. |
Ion channel modulators
|
US11505554B2
(en)
|
2019-05-31 |
2022-11-22 |
Praxis Precision Medicines, Inc. |
Substituted pyridines as ion channel modulators
|
TWI770527B
(zh)
|
2019-06-14 |
2022-07-11 |
美商基利科學股份有限公司 |
Cot 調節劑及其使用方法
|
JP2022540253A
(ja)
|
2019-07-11 |
2022-09-14 |
プラクシス プレシジョン メディシンズ, インコーポレイテッド |
T型カルシウムチャネル調節因子の製剤およびその使用方法
|
CA3154566A1
(en)
|
2019-09-18 |
2021-03-25 |
Prelude Therapeutics Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
AU2020351782A1
(en)
|
2019-09-26 |
2022-04-21 |
Exelixis, Inc. |
Pyridone compounds and methods of use in the modulation of a protein kinase
|
CN114727999A
(zh)
|
2019-11-26 |
2022-07-08 |
吉利德科学公司 |
用于预防hiv的衣壳抑制剂
|
US20230348466A1
(en)
|
2019-11-27 |
2023-11-02 |
Praxis Precision Medicines, Inc. |
Formulations of ion channel modulators and methods of preparation and use of ion channel modulators
|
US20230128972A1
(en)
|
2020-01-31 |
2023-04-27 |
Atomwise Inc. |
Anat Inhibitors and Methods of Use Thereof
|
WO2021173522A1
(en)
|
2020-02-24 |
2021-09-02 |
Gilead Sciences, Inc. |
Tetracyclic compounds for treating hiv infection
|
CA3171473A1
(en)
|
2020-02-24 |
2021-09-02 |
Exelixis, Inc. |
Compounds and methods of use
|
CA3175541A1
(en)
|
2020-03-30 |
2021-10-07 |
Gilead Sciences, Inc. |
Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
|
CA3176429A1
(en)
|
2020-03-31 |
2021-10-07 |
Global Blood Therapeutics, Inc. |
Modulators of hemoglobin
|
EP4126876A1
(en)
|
2020-04-01 |
2023-02-08 |
Global Blood Therapeutics, Inc. |
Pyrrolidine-pyrazoles as pyruvate kinase activators
|
TWI778562B
(zh)
|
2020-04-02 |
2022-09-21 |
美商基利科學股份有限公司 |
製備cot抑制劑化合物的方法
|
US10836757B1
(en)
|
2020-04-02 |
2020-11-17 |
Neurogastrx, Inc. |
Polymorphic forms of metopimazine
|
WO2021211922A1
(en)
|
2020-04-16 |
2021-10-21 |
Prelude Therapeutics, Incorporated |
Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
|
CA3181577A1
(en)
|
2020-04-28 |
2021-11-04 |
Global Blood Therapeutics, Inc. |
Thieno pyrimidines as ferroportin inhibitors
|
WO2021222483A1
(en)
|
2020-04-28 |
2021-11-04 |
Global Blood Therapeutics, Inc. |
Methods of use for pyrimidines as ferroportin inhibitors
|
EP4143178A1
(en)
|
2020-04-28 |
2023-03-08 |
Global Blood Therapeutics, Inc. |
Cycloalkyl pyrimidines as ferroportin inhibitors
|
WO2021231737A1
(en)
|
2020-05-13 |
2021-11-18 |
Prelude Therapeutics, Incorporated |
Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
|
JP2023529908A
(ja)
|
2020-06-09 |
2023-07-12 |
プレリュード・セラピューティクス・インコーポレイテッド |
Brm標的化化合物及び関連する使用方法
|
CN115996925A
(zh)
|
2020-06-25 |
2023-04-21 |
吉利德科学公司 |
用于治疗hiv的衣壳抑制剂
|
CA3190593A1
(en)
|
2020-08-03 |
2022-02-10 |
Global Blood Therapeutics, Inc. |
Urea derivatives as pyruvate kinase activators
|
US20240011030A1
(en)
|
2020-08-10 |
2024-01-11 |
Novartis Ag |
Treatments for retinal degenerative diseases
|
AU2021345423A1
(en)
|
2020-09-21 |
2023-05-11 |
Prelude Therapeutics, Incorporated |
Cdk inhibitors and their use as pharmaceuticals
|
KR20230079137A
(ko)
|
2020-09-30 |
2023-06-05 |
길리애드 사이언시즈, 인코포레이티드 |
가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
|
WO2022069701A1
(en)
|
2020-10-01 |
2022-04-07 |
Nogra Pharma Limited |
Methods of treating pulmonary fibrosis
|
US11773088B2
(en)
|
2020-11-02 |
2023-10-03 |
Praxis Precision Medicines, Inc. |
KCNT1 inhibitors and methods of use
|
KR20230117577A
(ko)
|
2020-11-06 |
2023-08-08 |
프렐루드 테라퓨틱스, 인코포레이티드 |
Brm을 표적으로 하는 화합물 및 연관된 사용 방법
|
AU2021401403A1
(en)
|
2020-12-18 |
2023-07-13 |
Prelude Therapeutics Incorporated |
Cdk inhibitors and their use as pharmaceuticals
|
EP4267559A1
(en)
|
2020-12-22 |
2023-11-01 |
Gilead Sciences, Inc. |
Substituted indole compounds
|
EP4267560A1
(en)
|
2020-12-22 |
2023-11-01 |
Gilead Sciences, Inc. |
6-substituted indole compounds
|
WO2022136509A1
(en)
|
2020-12-23 |
2022-06-30 |
Actelion Pharmaceuticals Ltd |
Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
|
MX2023007793A
(es)
|
2020-12-30 |
2023-09-22 |
Tyra Biosciences Inc |
Compuestos de indazol como inhibidores de cinasas.
|
LT4196479T
(lt)
|
2021-01-19 |
2023-12-11 |
Gilead Sciences, Inc. |
Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai
|
TW202245758A
(zh)
|
2021-02-08 |
2022-12-01 |
美商全球血液治療公司 |
作為丙酮酸激酶活化劑之吡咯啶-吡唑
|
JP2024505721A
(ja)
|
2021-02-09 |
2024-02-07 |
ギリアード サイエンシーズ, インコーポレイテッド |
チエノピロール化合物
|
US20240158393A1
(en)
|
2021-02-19 |
2024-05-16 |
Exelixis, Inc. |
Pyridone compounds and methods of use
|
US11661431B2
(en)
|
2021-04-16 |
2023-05-30 |
Gilead Sciences, Inc. |
Thienopyrrole compounds
|
CA3219786A1
(en)
|
2021-05-14 |
2022-11-17 |
Global Blood Therapeutics, Inc. |
Solid forms of a modulator of hemoglobin
|
TW202304435A
(zh)
|
2021-06-04 |
2023-02-01 |
美商基利科學股份有限公司 |
治療nash之方法
|
WO2022266370A1
(en)
|
2021-06-17 |
2022-12-22 |
Aria Pharmaceuticals, Inc. |
Sparsentan for treating idiopathic pulmonary fibrosis
|
TW202311256A
(zh)
|
2021-06-18 |
2023-03-16 |
美商基利科學股份有限公司 |
用於治療fxr誘發之搔癢之il-31調節劑
|
WO2023279041A1
(en)
|
2021-06-30 |
2023-01-05 |
Tyra Biosciences, Inc. |
Indazole compounds
|
WO2023278843A2
(en)
|
2021-07-02 |
2023-01-05 |
Acer Therapeutics, Inc. |
Solid forms of osanetant
|
WO2023287787A1
(en)
|
2021-07-13 |
2023-01-19 |
Prelude Therapeutics, Incorporated |
Brm targeting compounds and associated methods of use
|
TW202313053A
(zh)
|
2021-07-30 |
2023-04-01 |
瑞士商艾克泰聯製藥有限公司 |
吡唑并嘧啶及其作為pdgfr抑制劑之用途
|
WO2023034530A1
(en)
|
2021-09-02 |
2023-03-09 |
Teon Therapeutics, Inc. |
Methods of improving growth and function of immune cells
|
WO2023039464A1
(en)
|
2021-09-10 |
2023-03-16 |
Gilead Sciences, Inc. |
Thienopyrrole compounds
|
US20230144528A1
(en)
|
2021-09-30 |
2023-05-11 |
Prelude Therapeutics Incorporated |
CDK Inhibitors And Their Use As Pharmaceuticals
|
WO2023060134A1
(en)
|
2021-10-06 |
2023-04-13 |
Global Blood Therapeutics, Inc. |
Lactam pyrrolidine-pyrazoles as pyruvate kinase activators
|
WO2023076404A1
(en)
|
2021-10-27 |
2023-05-04 |
Aria Pharmaceuticals, Inc. |
Methods for treating systemic lupus erythematosus
|
WO2023081730A1
(en)
|
2021-11-03 |
2023-05-11 |
Teon Therapeutics, Inc. |
4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
|
WO2023097233A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic cyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
WO2023097230A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic bicyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
WO2023097234A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
WO2023102523A1
(en)
|
2021-12-03 |
2023-06-08 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
AU2022401696A1
(en)
|
2021-12-03 |
2024-05-09 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
WO2023102529A1
(en)
|
2021-12-03 |
2023-06-08 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
AU2022408097A1
(en)
|
2021-12-10 |
2024-05-30 |
Global Blood Therapeutics, Inc. |
Methods of administering a modulator of hemoglobin
|
US11939340B2
(en)
|
2022-01-21 |
2024-03-26 |
Prelude Therapeutics Incorporated |
CDK inhibitors and their use as pharmaceuticals
|
WO2023147312A1
(en)
|
2022-01-25 |
2023-08-03 |
Evvia Therapeutics, Inc. |
Ampk agonists and methods of use thereof
|
WO2023147135A1
(en)
|
2022-01-31 |
2023-08-03 |
Acer Therapeutics, Inc. |
Nk receptor antagonists for treatment of prostate cancer
|
WO2023147134A2
(en)
|
2022-01-31 |
2023-08-03 |
Acer Therapeutics, Inc. |
Methods for treating patients having low estrogen with nk3 antagonists
|
US20230257394A1
(en)
|
2022-02-03 |
2023-08-17 |
Prelude Therapeutics, Incorporated |
CDK Inhibitors And Their Use As Pharmaceuticals
|
WO2023172957A1
(en)
|
2022-03-09 |
2023-09-14 |
Prelude Therapeutics, Incorporated |
Thaizole-pyrimdiine cdk inhibitors and their use as pharmaceuticals
|
WO2023178547A1
(en)
|
2022-03-23 |
2023-09-28 |
Prelude Therapeutics, Incorporated |
Polymorphic compounds and uses thereof
|
US20240124422A1
(en)
|
2022-03-29 |
2024-04-18 |
Prelude Therapeutics Incorporated |
Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
|
WO2023192506A1
(en)
|
2022-03-31 |
2023-10-05 |
Rarified Biosciences, Inc. |
Malt1 modulators and uses thereof
|
TW202400172A
(zh)
|
2022-04-06 |
2024-01-01 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
WO2023215220A1
(en)
|
2022-05-02 |
2023-11-09 |
Esperion Therapeutics, Inc. |
Macrocyclic inhibitors of atp citrate lyase
|
WO2023220577A1
(en)
|
2022-05-10 |
2023-11-16 |
Prelude Therapeutics, Incorporated |
6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer
|
WO2023225162A1
(en)
|
2022-05-20 |
2023-11-23 |
Gilead Sciences, Inc. |
Antiviral indolinyl compounds and uses thereof
|
WO2023244584A1
(en)
|
2022-06-14 |
2023-12-21 |
Amygdala Neurosciences, Inc. |
Aldh-2 inhibitor compounds and methods of use
|
US20230399299A1
(en)
|
2022-06-14 |
2023-12-14 |
Amygdala Neurosciences, Inc. |
Aldh-2 inhibitor compounds and methods of use
|
US20230416240A1
(en)
|
2022-06-16 |
2023-12-28 |
Prelude Therapeutics Incorporated |
Kat6 targeting compounds
|
WO2023247595A1
(en)
|
2022-06-22 |
2023-12-28 |
Actelion Pharmaceuticals Ltd |
Pyrazolopyrazine carboxamides and their uses as pdgfr inhibitors
|
WO2023247590A1
(en)
|
2022-06-22 |
2023-12-28 |
Actelion Pharmaceuticals Ltd |
Triazolopyridine and benzoisoxazole carboxamides and their uses as pdgfr inhibitors
|
WO2023247596A1
(en)
|
2022-06-22 |
2023-12-28 |
Actelion Pharmaceuticals Ltd |
Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
|
WO2023247593A1
(en)
|
2022-06-22 |
2023-12-28 |
Actelion Pharmaceuticals Ltd |
Pyrrolopyridine carboxamides and their uses as pdgfr inhibitors
|
WO2024006897A1
(en)
|
2022-06-29 |
2024-01-04 |
Tyra Biosciences, Inc. |
Indazole compounds
|
WO2024006883A1
(en)
|
2022-06-29 |
2024-01-04 |
Tyra Biosciences, Inc. |
Polymorphic compounds and uses thereof
|
WO2024015827A1
(en)
|
2022-07-12 |
2024-01-18 |
Hotspot Therapeutics, Inc. |
Solid forms of a triazine derivative as cbl-b modulator
|
WO2024015372A1
(en)
|
2022-07-14 |
2024-01-18 |
Teon Therapeutics, Inc. |
Adenosine receptor antagonists and uses thereof
|
WO2024015416A1
(en)
|
2022-07-15 |
2024-01-18 |
Celloram Inc. |
Celastrol derivatives
|
WO2024013723A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|
WO2024047394A1
(en)
|
2022-08-31 |
2024-03-07 |
Otsuka Pharmaceutical Co., Ltd. |
Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine
|
WO2024077216A1
(en)
|
2022-10-06 |
2024-04-11 |
Prelude Therapeutics Incorporated |
Cdk inhibitors and their use as pharmaceuticals
|
WO2024089668A1
(en)
|
2022-10-28 |
2024-05-02 |
Basecamp Bio Inc. |
Somatostatin receptor 2 agonists and uses thereof
|
WO2024104968A1
(en)
|
2022-11-14 |
2024-05-23 |
Actelion Pharmaceuticals Ltd |
Pyrazolopyrrolopyridazines and their uses as pdgfr inhibitors
|
WO2024107711A1
(en)
|
2022-11-15 |
2024-05-23 |
Prelude Therapeutics Incorporated |
Brm targeting compounds and associated methods of use
|